Close mobile menu×

Gary K. Schwartz, MD

Expertise in: 
Cancer Care
Board Certifications: 
Medical Oncology, Internal Medicine
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-5098

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

NY Top Doctor

Board Certifications

  • Medical Oncology
  • Internal Medicine

Clinical Expertise

  • Cancer Care
  • Internal Medicine
  • Leiomyosarcoma
  • Medical Oncology
  • Melanoma
  • Sarcoma

Education & Training

  • MD, Albany Medical College
  • Albany Medical College
  • Residency: North Shore University Hospital
  • Fellowship: Mount Sinai Hospital

Honors & Awards

  • 2013 MSKCC Fellowship Solid Tumor Teach Award
  • 2009 Memorial Sloan-Kettering Teaching Excellence Award
  • 2006 New York State Teaching Award–Empire Clinical Research Investigator Program
  • 2006 Jeannik M. Littlefield–AACR Award in Metastatic Colon Cancer
  • 2003 Lustgarten Foundation for Pancreatic Research

About Gary Schwartz

I am a board-certified medical oncologist and internist and chief of Columbia University Medical Center's Division of Hematology and Oncology. I am actively involved in translational and clinical research. The lab, which I direct, focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of sarcoma and melanoma. However, these agents are not disease specific and hold promise in the treatment of all solid-tumor malignancies. These laboratory studies allow for a bridge between the laboratory and the clinic, and many of these drugs that originated in the lab are now being evaluated in clinical trials. My research studies have been supported by the National Cancer Institute, the Lustgarten Foundation for Pancreatic Cancer, the Department of Defense for Breast Cancer Research, the Byrne Foundation, and the Food and Drug Administration.

I am active in a number of professional organizations, including ALLIANCE for Clinical Trials in Oncology, the American Association of Cancer Research, the American Society of Clinical Oncology, and Radiotherapy Oncology Group. For several years, I have worked closely with the National Institutes of Health and served on a number of NIH review committees. Over the course of my career, I have received many awards, including the Lustgarten Foundation for Pancreatic Research, Jeannik M. Littlefield-AACR Award in Metastatic Colon Cancer and the New York State Teaching Award in the Empire Clinical Research Investigator Program. I have also been awarded a K12 award from the NCI for the training of the next generation of physician-scientists in cancer therapy. I am involved in the teaching and mentorship of junior faculty and fellows, and I take great pride in my active participation in patient care.

I have served on the editorial boards of a number of scientific journals, and I serve as associate editor on both the Journal of Clinical Oncology and Clinical Cancer Research. I am the author of nearly 200 papers and 17 book chapters.

Academic Titles

  • Professor of Medicine at CUMC

Administrative Positions

  • Division Chief, Hematology/Oncology
  • Associate Director, Herbert Irving Comprehensive Cancer Center

Committee/Societies/Council Memberships

Memberships and Positions

  • 2013–present:  Member, ASCO Cancer Education Committee – Sarcoma Track
  • 2012–present:   Member, ASCO Cancer Communications Committee
  • 2012:  Member, 2012 Clinical Scholar and Young Investigators Award Committee (Alliance for Clinical Trials in Oncology Foundation)
  • 2011–present:  Co-Chair, Experimental Therapeutics Committee, Alliance
  • 2011:  Member, Melanoma Foundation Grant Review Committee
  • 2010–present:  Member, NCI’s Experimental Therapeutics Program (NExT)
  • 2009–2011: Member, ASCO Grant Selection Committee


Editorial

  • 2013-Present: Associate Editor, Journal of Clinical Oncology
  • 2011: Associate Editorial Board Member, Frontiers in Pharmacology of Anti-Cancer Drugs
  • 2011: Editorial Board Member, Drug Discoveries & Therapeutics
  • 2011: Editorial Board Member, Investigational New Drugs
  • 2003-2006: Editorial Advisory Board, Cancer
  • 2000-Present: Associate Editor, Clinical Cancer Research
  • 2004-2008: Editorial Board Member, Journal of Clinical Oncology

Hospital Affiliations

  • NewYork-Presbyterian/Columbia
  • NewYork-Presbyterian/Lawrence Hospital

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Access (Exchange)
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

MagnaCare

Medicare

Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • SelectHealth

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Primary

Research

Research Interests

  • Melanoma
  • Sarcoma
  • Drug Development

Grants

Present Support               

  • 2013–2014:  Therapeutic Targeting of IDH1 and IDH2 Mutations in Acute Myeloid Leukemia (AML) and Chondrosarcoma; Principal Investigator; $300,000;Starr Cancer Consortium 15-A616
  • 2011–2015:  A Phase II Study of Pazopanib in Conjunction with Gemcitabine and Docetaxel (gem/doce/pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS);Co-PI; $279,536; NCCN
  • 2010–2015: Developing New Strategies for Targeting PDGFR/PI3K/AKT Pathways in Sarcoma; PI – Project 2; $205,612; Co-Director; Administrative Core; $112,340; NIH P50CA140146-03
  • 2010–2014: Development of Targeted Therapies for Ga/11 Mutant Melanoma; Co-Investigator; $150,000; Melanoma Research Alliance (MRA)
  • 2009–2014: Developing New Strategies for Targeting mTOR and IGF-1R/PI3/AKT Pathways in Sarcoma; Principal Investigator; $374,288; NIH R01 CA140331-04
  • 1995–2014: Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis; Co-Investigator; $135,153; U01 CA069856-16

A PHASE 1/1B STUDY OF MGCD516 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES (P&S Industry Clinical Trial)

Oct 8 2014 - Oct 8 2019

A PHASE 1 MULTIPLE ASCENDING DOSE STUDYOF DS-3032B, AN ORAL MDM2 INHIBITOR, IN SUBJECTS WITH ADVANCED SOLID TUMORS OR (P&S Industry Clinical Trial)

Sep 5 2014 - Sep 5 2019

EXPANDED ACCESS OF MK-3475 IN METASTATIC MELANOMA PATIENTS WITH LIMITED TO NO TREATMENT OPTIONS (P&S Industry Clinical Trial)

Aug 14 2014 - Aug 14 2019

A RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY OF SELUMETINIB (AZD6244, HYD-SULFATE) IN COMBINATION WITH DACARBAZINE COMPARED WITH PLACEBO (P&S Industry Clinical Trial)

Aug 8 2014 - Aug 8 2019

COLUMBIA UNIVERSITY MINORITY/UNDERSERVED SITE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (Federal Gov)

Aug 1 2014 - Jul 31 2019

CANCER CENTER SUPPORT GRANT (Federal Gov)

Jul 1 2014 - Jun 30 2019

DEVELOPMENT OF SGL-110 FOR THE TREATMENT OF BILLIARY CANCERS (Private)

Dec 1 2014 - Dec 31 2016

DEVELOPING NEW STRATEGIES FOR TARGETING MTOR AND IGF-1R/P13K/AKT PATHWAYS IN SARC (Federal Gov)

Jan 1 2014 - Jun 30 2015

PROJECT 2: DEVELOPING NEW STRATEGIES FOR TARGETING PDBFR/P13K/AKT PATHWAYS IN SARCOMA (Federal Gov)

Jan 1 2014 - Jun 30 2015

Selected Publications

  • Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, Thompson CB. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem. 2013;288(6):3804-15. PMCID: 3567635.
  •  Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK. Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model. Mol Cancer Ther. 2013.
  • Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013;14(4):371-82. PMCID: 3766955.
  • Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, Ustoyev Y, Crago AM, Singer S, Schwartz GK. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013;31(16):2024-8. PMCID: 3661937.
  • Dickson MA, Okuno SH, Keohan ML, Maki RG, D'Adamo DR, Akhurst TJ, Antonescu CR, Schwartz GK. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol. 2013;24(1):252-7.
  • Ambrosini G, Musi E, Ho AL, de Stanchina E, Schwartz GK. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol Cancer Ther. 2013;12(5):768-76. 
  • Luke JJ, D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res. 2012;18(9):2638-47. PMCID: 3343204.
  • Ho AL, Vasudeva SD, Lae M, Saito T, Barbashina V, Antonescu CR, Ladanyi M, Schwartz GK. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res. 2012;72(17):4515-25. PMCID: 3432680.
  • Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One. 2012;7(7):e40439. PMCID: 3393714.
  • Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, Courtney R, O'Dwyer PJ. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104(12):1862-8. PMCID: 3111206.
  • Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-34.